English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

The aim of study was analysis of the treatment results of the ALL IC-BFM 2002 trial in patients with acute lymphoblastic leukemia (ALL) treated in Polish pediatric oncohematology centres. Between November 2002 and November 2011, 1872 children aged 1-17 with newly diagnosed ALL were consecutively enrolled in the ALL IC BFM 2002 protocol. The follow-up was updated as of December 31, 2016. The study group included 56.6% males and 43.4% females. According to risk stratification, 32.6% of the children were qualified for a standard risk group (SR), 48.1% - intermediate risk (IR), 19.3% - high risk (HR). A total of 268 (14.3%) deaths were noted in the entire group. Cumulative death risk in SR group after 5 years was estimated at 4.4%, 14.2% in IR group, and 37.3% in HR. The incidence of death at complete remission (CR) was significantly higher in children aged ≥10 versus younger children (9.3% v 2.6%; P<0.001), in T-ALL versus BCP-ALL (9% v 3.5%; P<0.001), but differences were not found between girls and boys (4.0% v 4.5%; P=0.7). Relapses occurred in 275 children (14.7%), of which 51 cases occurred in SR group (8.4% of the patients who were stratified for the SR group), 147 in IR (16.4%), 77 in HR (21.2%). Overall survival for 1872 children with ALL was 86% after 5 years, whereas the EFS rate was 79%. ALL IC-BFM 2002 proved as a highly effective protocol for treatment of children with ALL in Polish pediatric oncohematology centres. This article is protected by copyright. All rights reserved.

Long‐term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC‐BFM 2002 trial